56,384 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Acquired by WINTON GROUP Ltd

WINTON GROUP Ltd acquired a new position in Hims & Hers Health, Inc. (NYSE:HIMSGet Rating) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 56,384 shares of the company’s stock, valued at approximately $255,000.

A number of other hedge funds also recently added to or reduced their stakes in the company. Northern Trust Corp raised its holdings in Hims & Hers Health by 1.3% in the 1st quarter. Northern Trust Corp now owns 253,307 shares of the company’s stock worth $1,350,000 after acquiring an additional 3,226 shares during the last quarter. Royal Bank of Canada raised its stake in Hims & Hers Health by 18.4% during the 1st quarter. Royal Bank of Canada now owns 26,523 shares of the company’s stock valued at $140,000 after buying an additional 4,126 shares during the last quarter. Captrust Financial Advisors raised its stake in Hims & Hers Health by 1,827.4% during the 1st quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock valued at $36,000 after buying an additional 6,414 shares during the last quarter. Arizona State Retirement System grew its position in shares of Hims & Hers Health by 51.2% during the 2nd quarter. Arizona State Retirement System now owns 31,973 shares of the company’s stock valued at $145,000 after acquiring an additional 10,830 shares during the period. Finally, Swiss National Bank grew its position in shares of Hims & Hers Health by 7.9% during the 1st quarter. Swiss National Bank now owns 185,000 shares of the company’s stock valued at $986,000 after acquiring an additional 13,500 shares during the period. 43.41% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $5.78 on Monday. The company has a market capitalization of $1.20 billion, a P/E ratio of -13.76 and a beta of 0.40. The company has a fifty day moving average of $5.23 and a 200 day moving average of $5.16. Hims & Hers Health, Inc. has a fifty-two week low of $2.72 and a fifty-two week high of $7.60.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HIMS. Guggenheim boosted their price objective on shares of Hims & Hers Health to $12.00 in a research report on Monday, August 15th. Bank of America raised shares of Hims & Hers Health from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $7.50 to $8.50 in a research report on Tuesday, November 8th. Citigroup boosted their price objective on shares of Hims & Hers Health from $8.00 to $9.00 in a research report on Tuesday, November 15th. Truist Financial assumed coverage on shares of Hims & Hers Health in a research report on Wednesday, September 7th. They set a “hold” rating and a $7.00 price objective for the company. Finally, Credit Suisse Group upped their target price on shares of Hims & Hers Health from $7.00 to $8.00 and gave the stock an “outperform” rating in a report on Wednesday, August 10th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Moderate Buy” and a consensus price target of $7.83.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 22,003 shares of the stock in a transaction dated Friday, October 14th. The shares were sold at an average price of $5.04, for a total transaction of $110,895.12. Following the completion of the transaction, the insider now owns 340,601 shares of the company’s stock, valued at approximately $1,716,629.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Hims & Hers Health news, Director Lynne Chou O’keefe sold 10,046 shares of the stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $5.68, for a total transaction of $57,061.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Soleil Boughton sold 22,003 shares of the stock in a transaction dated Friday, October 14th. The shares were sold at an average price of $5.04, for a total transaction of $110,895.12. Following the transaction, the insider now directly owns 340,601 shares of the company’s stock, valued at approximately $1,716,629.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 80,504 shares of company stock valued at $454,401. Company insiders own 35.22% of the company’s stock.

About Hims & Hers Health

(Get Rating)

Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.

Further Reading

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMSGet Rating).

Institutional Ownership by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.